anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Kits providing a combination of one or more pharmaceutical information comprising one or more agent(s) for the treatment or alleviation of symptoms commonly associated with a cold and an immunonutritional composition comprising immunonutritional agent and methods of using these kits are described. The kits provide both the pharmaceutical agent(s) and the immunonutritional agent in a convenient form for administration. The kit typically includes instruction for coordinating the administration of the pharmaceutical formulation with the administration of the immunonutritional composition. The preferred immunonutritional agents are compounds that contain a pharmaceutically acceptable form of zinc, such as zinc acetate, zinc gluconate, zinc gluconate glycine, and zinc sulfate. Preferably the kit contains multiple dosage forms containing the immunonutritional composition. In the most preferred embodiment, the immunonutritional composition is in the form of a lozenge. Suitable pharmaceutical agents include but are not limited to antihistamines, decongestants, anticholinergics, antitussives, analgesics, mucolytics, expectorants, and combinations thereof. The pharmaceutical formulations may be in any suitable dosage form, including forms which provide controlled release of the pharmaceutical agent, including immediate, sustained, modified, delayed or pulsed release pharmacokinetic mechanism or a combination thereof. The combined treatment requires administration of both the pharmaceutical formulation(s) for the treatment of symptoms commonly associated with a cold and the administration of the immunonutritional composition, which supplies nutritional support for the patient&#39;s innate immune response to the presence of infectious organisms.
A nutrient fiber matrix and associated methods that help control blood sugar levels is described. The matrix can control blood sugar in a variety of ways. In one possible example, the matrix blocks carbohydrates in a manner that reduces the body&#39;s ability to take the carbohydrates into its cells. In another example, the matrix acts to increase a person&#39;s energy level and feelings of satiety. Thus, the matrix can reduce the person&#39;s desire to consume more food and, thereby, help the person to keep from increasing his or her blood sugar levels by eating more. In still another example, the fiber matrix helps sugars to be absorbed over a longer period of time so as to smooth out and prevent spikes in blood sugar levels.
The invention discloses spleen-invigorating and food-retention removing nutritional powder for children. The spleen-invigorating and food-retention removing nutritional powder for children is developed with great concentration according to a physiological characteristic of &#39;superabundance often exists in liver and hypoactivity often exists in spleen&#39; of infants and young children and the characteristic that most of infants and young children are inadequate in natural endowment and need nutrition supplement, and consists of twenty traditional Chinese medicines including rice, radix astragali and the like. Codonopsis pilosula and white atractylodes rhizome invigorate middle energizer, benefit vital energy and the spleen and eliminate dampness. Tuckahoe invigorates the spleen, alleviates water retention, checks diarrhea and has the effect of decoction of four noble drugs. The radix astragali and Chinese angelica nourish the vitality, promote blood and have the effect of hematogenesis soup. Hawthorn and cutin internal walls promote digestion and remove food retention and promote the vital energy circulation. Cardamom kernels regulate the vital energy, stimulate appetite, check diarrhea and control nocturnal emission. Hyacinth beans invigorate the spleen and the vital energy, clear heat and promote diuresis. Chinese yam strengthens spleen and kidney. Rehmannia rhizome clears deficient heat, balances yin and yang and enables the fruits of Rangoon creeper and parasites to be removed. The rice mainly accounts for 80 % of total amount. The Nutritional powder for invigorating the spleen and removing the food retention of the children strengthens vital energy and produces blood, invigorates the middle energizer, stimulates the appetite, invigorates spleen to promote digestion, nourishes kidney, strengthens bones, gets rid of intestinal parasites, reduces the food retention, promotes growth and development, enables foreheads of the infants and the young children to jointed quickly, enables hair to be grow early, enables the infants and the young children to speak and walk early, enables intestines and stomach to be good, and enables the infants and the young children to grow tall and fat and have good health.
PURPOSE:To obtain a light screening packaged magerial, capable of inhibiting the photodegradatin of a photodegradable medicine containing the accommodated medicine seen through from the outside, by using a light screening film having a specific condition. CONSTITUTION:A packaged PTP (press through pack) or heat-sealed material which is a light screeening packaged material of a photodegradable medicine is obtained by using a light screening film, e.g. a light screening film corresponding to a concentration of a pigment 3-5 times that in &#39;&#39;VSS1101 UV3 Brown 4-670 &#39;&#39;, made of vinyl chloride, having a thickness of 250mum, and manfactured by SUMITOMO BAKELITE KK, transmitting 40% or more rays of wavelengths &gt;=600nm without transmitting rays of wavelengths &lt;=500nm. A dihydropyridine compound, e.g. nifedipine or nicardipine, may be cited as the photodegradable medicine. A vinyl chloride film having a thickness of 200-350mum is used for the PTP packaging, and polyethylene film, cellophane polyethylene laminate film, etc. having a thickness of about 80mum is used for the heat-sealing packaging.
Nearly 85% of stroke survivors experience significant unilateral impairment in upper extremity motor control, typically caused by damage to the corticospinal (CST) and corticoreticular (CRT) tracts (i.e., the corticofugal tracts). Alternative neural pathways, such as the contralesional cortico-reticulospinal tract (CRST), can be recruited to achieve movement of the affected arm and hand, but may have undesirable consequences. For example, the diffuse, bilateral branching of reticulospinal neurons can produce abnormal muscle co-activations (synergies) in the paretic limb, and involuntary mirror movements (associated reactions) between limbs. Together, these effects create stereotypical movement patterns post-stroke, and there is growing interest in novel \&#34;anti-synergy\&#34; interventions to enhance usage of residual CST systems rather than strengthening the CRST. Imaging has the potential to become an invaluable tool for evaluating whether rehabilitative strategies can preferentially access CST versus CRST pathways. However, current functional imaging research has focused on cortical activity, and must theoretically infer what pathway is used. Structural MRI directly assesses changes in white matter pathways, but it is limited to detecting long-term plasticity. To guide new interventions, there is a critical need to directly evaluate what descending motor pathways are active during movement. Thus, the overall objective of this study is to generate a novel fMRI dataset in participants with post-stroke hemiparesis, capturing neural activity during an innovative isometric shoulder abduction task, evaluating differences when abducting the paretic versus non-paretic arm. The investigators will acquire multi-echo fMRI data in individuals with post-stroke hemiparesis and age-matched controls, hypothesizing that increased reliance on the CRST will cause distinct activation patterns during shoulder abduction with the paretic limb, and that this will correlate with individual upper-extremity impairment (Upper-Extremity Fugl-Meyer Assessment). This work is significant because it will provide direct evidence of descending contralesional motor pathway involvement in post-stroke hemiparesis, and demonstrate the utility of neuroimaging for optimizing movements to preferentially engage specific systems and promote desired neural plasticity following injury.
PROBLEM TO BE SOLVED: To enable dosing of medical powder from children to adults with a simple operation. SOLUTION: A separation distance L1 between spray ports 20A of medical powder spray nozzle parts 20 is set at 12-25mm to allow proper insertion of spray ports 20A into nasal cavities of patients in a wide range from infants to adults. As the flow of the medical powder is shunted at a branch part 18 to be supplied to medical powder paths 19, the medical powder can be dosed simultaneously and evenly into right and left nasal cavity. Moreover, the capacity of a capsule is set at 0.1-1.4cc to allow thoroughly spraying of all of the medical powder in the capsule. As the passing sectional area of an air supply path 11 is set at 0.2-6.0mm&lt;2&gt; , air from a pump 13 can be supplied at a proper flow rate and at an appropriate flow velocity.  On the other hand, a manual type pump 13 with a delivery capacity of 10-60cc is mounted on an air supply part 6, thereby facilitating the supply of an air flow.
The present invention relates to a kind of drug payroll management methods, comprising: a. issues dispensing according to prescription information and instructs；B. by the drug dispensing in prescription into medicine basket, medicine basket is distributed to foreground window；C. judge whether there is refrigeration medicine in the medicine basket of foreground window, if there is refrigerating medicine, then judge whether the refrigeration medicine is overtime, enters step d, otherwise goes to step e；D. if the refrigeration medicine time-out, the medicine basket equipped with the refrigeration medicine light a kind of lamp of color, otherwise go to step e；E. judge whether prescription medicine is provided overtime: if prescription medicine provides time-out, the medicine basket equipped with the prescription medicine lights the lamp of another color, and otherwise go to step f；F. patient&#39;s medicine basket when taking medicine equipped with patient drug of swiping the card lights the lamp of the third color.The invention further relates to a kind of drug release management systems.The present invention can improve the overstocked problem of the medicine basket occurred in drug distribution process, and provide advantageous support in terms of dispensing time-out, refrigeration medicine take out.
The invention discloses an external hot-compress powder, and especially relates to a cervical and lumbar vertebra collateral-freeing hot-compress powder. The hot-compress powder is prepared by grinding and mixing the following raw materials by weight: 30 grams of monkshood, 30 grams of aconitum kusnezoffii, 30 grams of cassia bark, 30 grams of dry ginger, 20 grams of dahurian angelica root, 20 grams of arisaema heterophyllum blume, 20 grams of red peony root, and 30 grams of camphor. The using method of the powder comprises the following steps: mixing and grinding the medicinal raw materials mentioned above into fine powder, weighing 30 to 60 grams of the powder for each time, adding edible vinegar into the powder, blending the mixture into paste, paving the paste on gauze, and finally pasting the gauze on the sore part. The powder is developed on the basis of the nerve distribution, the distribution relationship between the anterior branch and the posterior branch, and is accord with the biomechanics theory and the circulation parts of the muscle and ligament. At the same time, the traditional Chinese medicine theory is also taken into account, the internal organ theory and meridian and collateral theory are utilized, and the overall pain source namely &#34;Tonggen&#34; acupoint is selected. The powder has the functions of freeing the collateral, dissipating cold, dispelling wind, removing dampness, moving stagnation, diminishing stasis, activating blood, and relieving pains, and is capable of treating cervical spondylosis, protrusion of lumbar intervertebral disc, hyperostosis, spinal stenosis, sciatica, shoulder periarthritis, and gonitis under the assistance of acupuncture needle treatment.
1318554 Intrauterine devices MICHAEL REESE HOSPITAL &amp; MEDICAL CENTER 12 June 1970 [16 June 1969] 28616/70 Heading A5R An intrauterine device comprises at least one capsule containing a progestin contained within a partially permeable wall. In the embodiment shown in Fig. 1, the device comprises three silicone elastomer tubes 11, 12, 13 containing progestin. These tubes are joined by polyethylene corner pieces 14, 15, 16 so that the whole aquires a generally triangular shape. In other embodiments (not shown) the device may comprise rings, spirals, bows or double S loops. The triangular device may be elastically distended so that it is easily inserted into the uterus using the forked applicator (21) and a string (22) (Fig. 2). Oncee the device is in place the capsules slowly release the progestin at a rate dependent upon the directions of the capsule walls. The recommended progestin is d1-11#-ethyl-17a-ethinyl-17#-hydroxygon-4-ene -3-one although others are exemplified.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide royal jelly-containing gene expression inhibitors and gene expression promoters; and to provide a method of detecting them.  &lt;P&gt;SOLUTION: Gene expression inhibitors containing royal jelly or its fraction have an effect of inhibiting expression of genes containing at least one base sequence selected from SEQ ID Nos. 1 to 5, and gene expression promoters containing royal jelly or its fraction have an effect of promoting expression of genes containing at least one base sequence selected from SEQ ID Nos. 6 to 13. The gene expression inhibitors or the gene expression promoters have anti-inflammatory effects, keratinization abnormality accumulation inhibiting effects, wound-healing promoting effects and/or moistening effects.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic which can simply remove keratotic plug incapable of being removed with ordinary cleansing cosmetics.  &lt;P&gt;SOLUTION: This cleansing cosmetic is characterized by containing (1) a dibasic acid di(2 to 5C) ester and (2) an N-acyl sarcosine or its ester. The acyl group in the N-acyl sarcosine or its ester is preferably a 10 to 24C acyl group. It is preferable that the cleansing cosmetic is a cosmetic aiming the removal of keratotic plugs. In addition, it is preferable to contain a carbonic diester.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a spot curing lens which can be used together with a dental curing device for spot curing an overlay, inlay, veneer, crown, or other dental appliance to a patient&#39;s tooth.  &lt;P&gt;SOLUTION: The spot curing lens 10 includes a base part 12, a lens main body 14, a wall 16, and a spherical focusing lens 18 placed in the hollow inside defined by the lens main body 14. The base part 12 is constructed so as to allow the lens 10 to be removably attached to an illuminating device. The spot curing lens 10 is attached to an intermediate focusing lens 19 which really itself is (integrally or detachably) attached to the illuminating device. The intermediate lens 19 is an arbitrary one and the spot curing lens 10 can be directly attached to the illuminating device by a desired attaching means widely known in this technical field.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject composition excellent in coloring activities, capable of readily used and capable of naturally enabling the hair to be inconspicuous by allowing the composition to include a specific amide compound and a compound selected from pyrogallol, etc. SOLUTION: This hair dye composition contains (A) an amide compound having 0-50 deg.C melting point, preferably of an N-substituted amide compound having &gt;=30 total number of carbons, or the like, (B) one or more kinds selected from pyrogallol, a hydration or condensation tannin, gallic acid or an ester thereof (e.g. propyl gallate), and a plant extract containing a polyphenol (e.g. the extract of Saxifraga stolonifera), preferably in the proportions of 0.1-20 wt.% component A and 0.1-3.0 wt.% component B based on the whole composition. Preferably, a polyvalent metal salt such as ferrous sulfate is further included therein. The composition can gradually make a black hair lighter and change the nuance of the hair.
A non-liquid carrier for topical application, in particular a soap, contains as a deodorizing agent a water-soluble chelate complex of a b -diketone and copper, magnesium, calcium, zinc, cadmium, aluminium, zirconium, antimony or cobalt, the b -diketone of said complex containing on its carbon atom bridging the keto groups at least one hydrogen atom.  Specified soap tablets contain curd soap, ethyl alcohol and copper 3-acetyl-2,4-pentanedionate or antimony acetyl acetonate.ALSO:Copper acetyl acetonate, copper 5-phenyl-2,4-pentanedionate, zirconium 2,4-heptanedionate, calcium 2,4-heptanedionate, cadmium 2,4-hexanedionate, magnesium acetyl acetonate, aluminium acetyl acetonate, copper 3-chloro-2,4-pentanedionate, copper p-aminobenzoyl acetonate, copper 3-acetoxy-2,4-pentanedionate, copper p-methylbenzoyl acetonate, calcium 2,4-octanedionate, zirconium benzoyl acetonate, cobalt 3-n-dodecyl-2,4-pentanedionate, copper 3-acetyl-2,4-pentanedionate, antimony acetyl acetonate, zirconium 2 - methyl-4,6-heptanedionate, copper 2,2-dimethyl-3,5-hexanedionate and copper 2-methyl-3,5-heptanedionate are prepared by reacting a salt of the metal with the corresponding b -diketone.ALSO:Textile materials in particular dress preservers and diapers contain as a deodorising agent a water-soluble chelate complex of a b -diketone and copper, magnesium, calcium, zinc, cadmium, aluminium, zirconium, antimony or cobalt, the b -diketone of said complex containing on its carbon atom bridging the beta groups at least one hydrogen atom.  Specified active ingredients are aluminium acetylacetonate, copper 3-acetoxy-2,4,-pentanedionate or copper 2-methyl-3,5-heptanedionate.ALSO:A textile material or a non-liquid carrier material for topical application to human beings, contains as a deodorizing agent a water-soluble chelate complex of a b -diketone and copper, magnesium, calcium, zinc, cadmium, aluminium, zirconium, antimony or cobalt, the b -diketone of said complex containing on its carbon atom bridging the keto groups at least one hydrogen atom. The preferred b -diketones are those of formula &lt;FORM:0901554/VI/1&gt; where X is a hydrogen or halogen atom, an acyl, acyloxy, alkyl, aryl or aralkyl group and Y is a substituted or unsubstituted alkyl, aralkyl or aryl group.  Specified active ingredients are zirconium acetyl acetonate, cobalt acetyl acetonate; copper 5-phenyl-2,4-pentanedionate, zirconium, 2,4-heptanedionate, cadmium 2,4-heptanedionate, calcium 2,4-octanedionate, cobalt 3-n-dodecyl-2,4-pentanedionate, copper 2,2-dimethyl-3,5-hexanedionate and many others.  Specified materials are powders, soaps, pastes, creams, ointments, sweatsticks, vaginal tampons, cellulosic fibre fleeces, diapers, dress-preservers, sanitary napkins and insoles. The compositions for topical application contain as additives, adepslanae, beeswax, olive oil, perfume oils, silica gel, stearin, isopropyl palmitate, sorbitan monostearate, polyalkylene oxide, sorbitan monostearate, sorbitol, propylene glycol, talcum, starch, tragacanth and ethyl alcohol.
The present invention relates to a method for modulating stem cells proliferation or differentiation comprising a step of contacting said stem cells with an effective amount of an activator or inhibitor of a proprotein convertase subtilisin kexin 9 (PCSK9). Inventors performed a global transcriptomic analyses in hiPSCs and showed that PCSK9 inhibition by shRNA and the intracellular PCSK9-R104C/V114A mutation negatively regulate the NODAL signaling pathway and its targets. This regulation was manifested in drastic reduction P-SMAD2/total SMAD2 protein level. This was accompanied by reduced proliferation rate where hiPSC-shPCSK9 and hiPSC-R104C/V114A demanded &gt;1.3-fold more time to double compared to their control counterparts. They showed that PCSK9 was regulating this signaling pathway through direct physical interaction with DACT2, an intracellular attenuator of NODAL receptor and favoring its protein degradation. Thus, these findings allow to understand the differentiation and proliferation of cells.
The present invention relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject. The method involves administering to a subject an effective amount of a compound disclosed herein that modulates soluble adenylyl cyclase, under conditions effective to treat the disorder mediated by soluble adenylyl cyclase. The present invention also relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject, where the disorder is selected from the group consisting of learning or memory disorders, malaria, fungal infection, spinal cord injury, Alzheimer&#39;s disease, amyotrophic lateral sclerosis, and peripheral neuropathy.  The method involves modulating soluble adenylyl cyclase in the subject.  Another aspect of the present invention relates to a method of modulating soluble adenylyl cyclase. The method involves contacting eukaryotic cells with a compound that modulates soluble adenylyl cyclase, under conditions effective to modulate soluble adenylyl cyclase.
PCT No. PCT/GB95/00658 Sec. 371 Date Nov. 20, 1996 Sec. 102(e) Date Nov. 20, 1996 PCT Filed Mar. 23, 1995 PCT Pub. No. WO95/25718 PCT Pub. Date Sep. 28, 1995The present invention relates to compounds of general formula (I)    &lt;IMAGE&gt;  (I)  where R1 and R2, which may be the same or different, each represent a hydrogen atom or an aliphatic, cycloaliphatic, araliphatic or aryl group or together with the nitrogen atom to which they are attached form a heterocyclic group; R3 represents a methyl group having  alpha - or  beta -configuration; one of Ra and Rb represents a hydroxy group or protected hydroxy group and the other represents a hydrogen atom; Y represents a valence bond or an alkylene group containing up to 3 carbon atoms; and A= represents a cyclohexylidene moiety characteristic of the A-ring of a 1 alpha -hydroxylated vitamin D or analogue thereof. Active compounds of the invention exhibit separation of cell modulating and calcaemic activities coupled with enhanced duration of activity.
PURPOSE: To provide an immunogen derived from the tumor cells treated to increase specific immunogenicity and an antitumor vaccine contg. the immunogen. CONSTITUTION: The modified tumor cells are prepd. by acting a crosslinking agent, 2&#39;,3&#39;-nucleoside or nucleotide aldehyde, more preferably the compd. of the formula (R is H, mono-, di- or triphosphate; B is the nucleotide base selected from adenine, guanine, cytosine, thymine, uracil and inosine) on the tumor cells at and for the concn. (more adequately &gt;=20 mM) and time sufficient for inducing the crosslinking of the protein in the plasma membrane of these cells and simultaneously applying an isostatic pressure of 1200 to 1400 atm. The immunogen capable of inducing an antitumor immunological reaction is derived from these cells.  Examples of the immunogen include the modified tumor whole cells, the plasma membranes obtainable therefrom and the protein type substances which are obtainable from the cells and membranes described above and substantially retain the capacity to induce the antitumor immunological reaction from the cells described above.